KIZOO Technology Ventures

Michael Greve, the founder and managing partner, leads all investment decisions. Greve co-founded 1&1 Internet, a pioneering European web-hosting company, and sold it to United Internet. After the exit, he redirected his capital and attention toward longevity biotechnology. There is no external investment committee; Greve operates with a small internal team of scientists who advise on technical due diligence.

KIZOO sources primarily through academic and scientific networks in aging research, including relationships with the Methuselah Foundation, SENS Research Foundation, and various European and US longevity hubs. Greve's personal involvement in the Forever Healthy Foundation provides additional inbound founder referrals. The firm does not rely on traditional venture deal flow from accelerator demo days or investment banks.

The firm concentrates on longevity biotechnology, including cellular senescence, gene therapy, epigenetic reprogramming, and AI-driven drug discovery. It also invests in computational biology, robotics for age-related conditions, and neurodegeneration platforms. KIZOO explicitly avoids consumer digital, enterprise SaaS, and fintech unless the technology has a direct therapeutic application in aging.

Yes. Because KIZOO is not constrained by fund reserve ratios, it can and does participate in follow-on rounds when the science merits continued support and the syndicate aligns. Greve has described the approach as 'patient capital' committed to the full development arc of a company, not just the initial seed phase.

Both entities were established by Michael Greve and share a mission focus on extending healthy human lifespan. The Forever Healthy Foundation is a non-profit that conducts philanthropic funding and public evaluation of rejuvenation therapies. KIZOO Technology Ventures is the for-profit investment vehicle. Greve maintains a firewall between the two, though their scientific advisory networks overlap.

KIZOO regularly co-invests alongside aligned syndicate partners such as Juvenescence, Bold Capital Partners, and other longevity-focused investors. It prefers syndicates where other participants share a multi-decade thesis on aging biology rather than traditional VC exit timelines. KIZOO does not anchor or lead large institutional rounds but participates actively in pre-seed and seed consortia.